Home > Healthcare > Biotechnology > Biotechnology R&D > Cell Dissociation Market
Cell Dissociation Market size was valued to be USD 378.3 million in 2022 and is expected to reach USD 1.6 billion in 2032, growing at a CAGR of 15.3% by 2032 driven by the rising focus on the development of cell-based therapeutics that has led to the development of patient-specific cell therapies.
Cell dissociation is essential for isolating and culturing cells. Also, there is a notable increase in interest and investment in cell-based research. Government, private firms, and biotechnology companies are dedicating substantial resources to support cell therapy technologies in areas such as stem cell biology, regenerative medicine, and immunotherapy. For instance, the U.S. National Institutes of Health (NIH) allocate significant funds around a billion dollars per year to support stem cell research. Additionally, collaborations and partnerships between academia and industry are common, facilitating research translation.
Report Attribute | Details |
---|---|
Base Year: | 2022 |
Cell Dissociation Market Size in 2022: | USD 378.3 Million |
Forecast Period: | 2023 to 2032 |
Forecast Period 2023 to 2032 CAGR: | 15.3% |
2032 Value Projection: | USD 1.6 Billion |
Historical Data for: | 2018 to 2022 |
No. of Pages: | 150 |
Tables, Charts & Figures: | 263 |
Segments covered: | Product, Application, End-user, and Region |
Growth Drivers: |
|
Pitfalls & Challenges: |
|
Cell dissociation refers to the process of separating and isolating individual cells or cell clusters from a tissue, organ, or cell culture. This process typically involves breaking down cell-to-cell and cell-to-substrate adhesions to release the constituent cells, allowing them to be suspended as individual entities in a solution.
The impact of COVID-19 on the cell dissociation market has been positive. Despite disruptions caused by lockdowns and social distancing measures, researchers continued to collaborate and conduct experiments remotely. The availability of cell dissociation products allowed some research to continue even in decentralized settings. The urgent need for vaccines and therapeutics to combat COVID-19 prompted a surge in research activities. The cell dissociation techniques and products played a vital role in the isolation and culture of cells for vaccine development, testing, and the production of monoclonal antibodies. As researchers searched for potential drug candidates to treat COVID-19, cell-based assays became essential for drug screening and testing.
The increasing focus on the development of cell-based therapeutics is a significant driver for the industry. Cell-based therapeutics, also known as cell therapies or regenerative medicine, involve the use of living cells to treat diseases, repair damaged tissues, and restore normal cellular function in patients. Cell dissociation is a critical step in the process of expanding cells for therapy. Researchers and manufacturers rely on effective dissociation techniques to isolate, culture, and expand cells to therapeutic numbers. Also, regenerative medicine often relies on tissue engineering approaches to create functional tissues and organs for transplantation.
While cell dissociation techniques and therapies hold immense promise for advancing medicine and biotechnology, the financial burden and resource-intensive nature of these endeavours can impact the cell dissociation market dynamics. Many research projects depend on grants and funding from government agencies, private foundations, and industry partners. Also, cell dissociation techniques often involve the use of specialized equipment and high-quality reagents, which can be expensive in nature. Researchers and institutions must allocate significant budgets to purchase, maintain, and replace this equipment and procure essential reagents for their experiments. Furthermore, ensuring the safety, purity, and efficacy of cell-based therapies requires rigorous quality control measures and validation processes. These additional steps can drive up costs as they demand specialized testing and compliance with regulatory standards.
Based on the product, the cell dissociation market is segmented into enzymatic dissociation, non-enzymatic dissociation, and instruments & accessories. Enzymatic dissociation is further divided into trypsin, collagenase, elastase, papain, hyaluronidase, DNase, and other enzymes. The enzymatic dissociation segment held the largest market share of 47.9% in 2022. Enzymes are highly effective at breaking down cell-to-cell and cell-to-substrate adhesions. They efficiently detach cells from culture surfaces and tissues, making them a preferred choice for routine cell dissociation applications. Also, enzymatic dissociation methods are versatile and compatible with a wide range of cell types and tissue sources. This versatility makes them suitable for various research and bioprocessing applications, from stem cell culture to cancer cell isolation. Moreover, they can be scaled up for industrial bioprocessing and large-scale cell culture applications. This scalability is essential to produce cell-based therapies and biologics.
Based on the application, the cell dissociation market is fragmented into tissue dissociation and cell detachment. The tissue dissociation segment dominated the market in 2022 and is expected to reach USD 842.5 million by 2032. Tissue dissociation methods are versatile and applicable to a wide range of research areas. They are used in cell biology, immunology, neuroscience, cancer research, regenerative medicine, and drug discovery. Researchers frequently require tissue dissociation techniques to isolate and study specific cell populations within various tissues. The pharmaceutical industry relies on tissue dissociation techniques to create cell-based assays for drug screening and testing. Dissociating tissues allows researchers to study how potential drugs interact with specific cell types and tissues, accelerating drug discovery and development. Furthermore, tissue dissociation is used to obtain cell populations for genomic and proteomic analyses, including DNA sequencing, gene expression profiling, and protein analysis.
Based on the end-user, the global cell dissociation market is divided into pharmaceuticals and biotechnology companies, research & academic institutes, CROs, and other end-users. The pharmaceuticals & biotechnology companies’ segment is expected to show significant expansion of 15.6% by 2032. Pharmaceutical & biotechnology companies are at the forefront of drug discovery and development. They heavily rely on cell dissociation techniques and models to screen potential drug candidates, study disease mechanisms, and evaluate drug safety and efficacy. Moreover, cell dissociation is essential for expanding cell lines, maintaining bioreactors, harvesting cells for biomanufacturing processes, and in the isolation and preparation of therapeutic cells, such as stem cells or immune cells. Also, the companies utilize cell dissociation to isolate patient-specific cells for research and therapeutic development, especially in the context of cancer and rare diseases.
In 2022, the North American cell dissociation market held the largest share of 37.2%. The market is being driven by favourable governments initiatives as well as due to the presence of numerous pharmaceutical and biotechnology companies. These companies heavily rely on cell dissociation techniques for various applications, including drug screening, biomanufacturing, and cell-based therapies. Additionally, biotech startups and established companies in North America are at the forefront of cutting-edge research, driving the adoption of advanced cell dissociation methods. Moreover, North American markets are known for their rapid adoption of innovative technologies and research tools. Companies in the region are quick to embrace advanced cell dissociation techniques that offer improved efficiency, precision, and cell viability.
Market players operating in the cell dissociation is as mentioned below:
In the cell dissociation market, market share is influenced by several key factors. For instance, Thermo Fisher Scientific, a prominent player in this field, maintains a robust market share due to its extensive product portfolio and continuous innovation. Their high-quality dissociation products are trusted by researchers worldwide, enhancing their brand reputation. Thermo Fisher's effective distribution networks and strategic partnerships ensure a broad customer reach. Also, their adherence to stringent regulatory standards, like Good Manufacturing Practices (GMP), adds to their credibility.
Click here to Buy Section of this Report
By Product
By Application
By End-user
The above information is provided for the following regions and countries: